ORBIMED ADVISORS LLC - 03 Nov 2026 Form 4 Insider Report for Electra Therapeutics, Inc. (ETRA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ETRA
Reported as of: 03 Nov 2026
Net transaction value: +$3,605,116
SEC form: 4
Accepted by SEC: 05 Nov 2026, 17:39:46 UTC
Prior SEC filing: 04 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Filing notes and source

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Electra Therapeutics, Inc. (ETRA) on 05 Nov 2026.

Key facts

This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Electra Therapeutics, Inc. (ETRA).
10 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Nov 2026, 17:39.

Change

Previous filing in this sequence was filed on 04 Nov 2026.
Current net transaction value: +$3,605,116.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship: Director, 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date: 05 Nov 2026

CIK 0001760648

OrbiMed Capital GP VII LLC

Relationship: Director, 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC
Signature date: 05 Nov 2026

CIK 0001808744

OrbiMed Genesis GP LLC

Relationship: Director, 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
Signature date: 05 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETRA transaction

Common Stock

Purchase

Transaction value: $190,614
Shares: +24,313
Change %: +0.47%
Price: $7.84
Shares after: 5,151,204
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $190,614
Shares: +24,313
Change %: +0.47%
Price: $7.84
Shares after: 5,151,204
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $190,614
Shares: +24,313
Change %: +0.47%
Price: $7.84
Shares after: 5,151,204
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $766,752
Shares: +97,800
Change %: +5.6%
Price: $7.84
Shares after: 1,856,079
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $766,752
Shares: +97,800
Change %: +5.6%
Price: $7.84
Shares after: 1,856,079
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $766,752
Shares: +97,800
Change %: +5.6%
Price: $7.84
Shares after: 1,856,079
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $192,272
Shares: +24,400
Change %: +0.47%
Price: $7.88
Shares after: 5,175,604
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $192,272
Shares: +24,400
Change %: +0.47%
Price: $7.88
Shares after: 5,175,604
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $192,272
Shares: +24,400
Change %: +0.47%
Price: $7.88
Shares after: 5,175,604
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $776,968
Shares: +98,600
Change %: +5.3%
Price: $7.88
Shares after: 1,954,679
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $776,968
Shares: +98,600
Change %: +5.3%
Price: $7.88
Shares after: 1,954,679
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $776,968
Shares: +98,600
Change %: +5.3%
Price: $7.88
Shares after: 1,954,679
Date: 03 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $72,097
Shares: +9,267
Change %: +0.18%
Price: $7.78
Shares after: 5,184,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $72,097
Shares: +9,267
Change %: +0.18%
Price: $7.78
Shares after: 5,184,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $72,097
Shares: +9,267
Change %: +0.18%
Price: $7.78
Shares after: 5,184,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $288,638
Shares: +37,100
Change %: +1.9%
Price: $7.78
Shares after: 1,991,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $288,638
Shares: +37,100
Change %: +1.9%
Price: $7.78
Shares after: 1,991,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $288,638
Shares: +37,100
Change %: +1.9%
Price: $7.78
Shares after: 1,991,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $35,350
Shares: +5,000
Change %: +0.1%
Price: $7.07
Shares after: 5,189,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $35,350
Shares: +5,000
Change %: +0.1%
Price: $7.07
Shares after: 5,189,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $35,350
Shares: +5,000
Change %: +0.1%
Price: $7.07
Shares after: 5,189,871
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $141,400
Shares: +20,000
Change %: +1%
Price: $7.07
Shares after: 2,011,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $141,400
Shares: +20,000
Change %: +1%
Price: $7.07
Shares after: 2,011,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $141,400
Shares: +20,000
Change %: +1%
Price: $7.07
Shares after: 2,011,779
Date: 04 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $225,813
Shares: +30,891
Change %: +0.6%
Price: $7.31
Shares after: 5,220,762
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $225,813
Shares: +30,891
Change %: +0.6%
Price: $7.31
Shares after: 5,220,762
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $225,813
Shares: +30,891
Change %: +0.6%
Price: $7.31
Shares after: 5,220,762
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F1, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $915,212
Shares: +125,200
Change %: +6.2%
Price: $7.31
Shares after: 2,136,979
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $915,212
Shares: +125,200
Change %: +6.2%
Price: $7.31
Shares after: 2,136,979
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

ETRA transaction

Common Stock

Purchase

Transaction value: $915,212
Shares: +125,200
Change %: +6.2%
Price: $7.31
Shares after: 2,136,979
Date: 05 Nov 2026
Ownership: See footnotes
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.

Footnote F2

These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.

Footnote F3

This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.